XTL BiopharmaceuticalsXTLB
13F holders, Q3 2024 (September 30)3holders −1
0new positions
1sold out
$2.40avg. 13F price*
At the end of Q3 2024, 3 institutions reported holding XTL Biopharmaceuticals Ltd. (XTLB) in their 13F filings, down 1 from Q2 2024. 0 opened new positions and 1 sold out. The largest holders were Noked Israel Ltd ($477K), Morgan Stanley ($64K) and Rhumbline Advisers ($16K).
- Company
- XTL Biopharmaceuticals Ltd.
- CUSIP
- 98386D307
- Latest filing quarter
- Q4 2025
History
Number of 13F holders
Total Exit/New Position Q2 2024 → Q3 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 1 | $37K |
All 13F filers, Q2 2024 → Q3 2024: 935 shares bought and 22,135 shares sold, net −21,200 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 3 holders
| Noked Israel Ltd | 0.10% | No change | 198,888 | $477K |
| Morgan Stanley | 0.00% | Reduce -20.2% | 26,451 | $64K |
| Rhumbline Advisers | 0.00% | Add +16.7% | 6,519 | $16K |
"% of holder's portfolio" is XTLB's weight in each manager's 13F, not the share of XTL Biopharmaceuticals Ltd. the manager owns.